Torsdag 23 Januari | 13:25:22 Europe / Stockholm

Prenumeration

2025-01-09 09:20:00

Redeye retains its Q4 and 2025 forecasts for Transtema. The new deal with TRV brings sales – raising our 2026 forecast slightly – and, more importantly, sets Transtema up for further public sector deals. We retain our positive view and our Base Case of SEK25.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/